Sanford Simon
August 12th, 2024
Recent Posts
- Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
- Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3’25 Financial Results Report in Mid-August
- Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
- Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
- Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
- Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
- Applied DNA’s LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
- Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test